AFP and hepatocellular carcinoma: Once NTBC treatment is initiated, excretion of SA is hampered, and the levels of alpha-fetoprotein (αFP)—the liver biomarker of HCC progression—decrease slowly over a few months, until they reach normal values [6,7,8].